ArticleBMC chemistry2026
Trace-level quantification of levofloxacin NDSRIs using LC-TQ-MS/MS: a multi-metric sustainability and integrated toxicological-analytical framework.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nitrosamine drug substance-related impurities (NDSRIs) have emerged as a critical regulatory concern due to their potential genotoxicity at trace levels, necessitating highly sensitive and scientifically robust analytical methodologies. Despite the widespread use of levofloxacin (LOX), no validated analytical method has been reported for the simultaneous determination of LOX-specific NDSRIs. Although several LC-MS/MS methods have recently been reported for NDSRIs associated with other pharmaceutical compounds, these studies primarily focused on compound-specific impurity monitoring and did not address levofloxacin-derived NDSRIs. Furthermore, most reported methodologies emphasize analytical sensitivity without integrating toxicological risk assessment and sustainability evaluation. In this study, a highly sensitive and selective LC-TQ-MS/MS method was developed and validated for the simultaneous trace-level quantification of N-nitroso methyl piperazine (N-NMP) and N-nitroso desmethyl levofloxacin (N-NDLOX) in LOX drug substance and tablet formulations. A systematic risk-based analytical development strategy was employed to define the Analytical Target Profile (ATP) and guide method development and optimization. Structural confirmation of the synthesized NDSRIs was achieved using advanced spectroscopic techniques, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.